Andreas Wollenberg

Safety of tralokinumab in patients with moderate-to-severe atopic dermatitis followed for up to 4.5 years: an integrated analysis of eight clinical trials.

Cost-Per-Responder Analysis for Tralokinumab and Dupilumab in Combination with Topical Corticosteroids in Patients with Moderate-To-Severe Atopic Dermatitis.

Sustained on/off-treatment disease control with abrocitinib for moderate-to-severe atopic dermatitis

Severity bands for atopic dermatitis measures: Analysis from adult dupilumab randomized clinical trials.

Matching-Adjusted Indirect Comparison of the Efficacy of Delgocitinib Cream and Dupilumab in the Treatment of Moderate to Severe Atopic Hand Eczema.

Long-Term Safety and Efficacy of Tralokinumab in Patients with Moderate-to-Severe Atopic Dermatitis Treated for up to 6 Years: Final Results from the Open-Label Extension Trial ECZTEND.

European Guideline (<scp>EuroGuiDerm</scp>) on atopic eczema: Living update

European Guideline (EuroGuiDerm) on atopic eczema: Living update.

Risk of developing sleep disorders and psychologic comorbidity in children with inflammatory skin diseases—A population-based study

Predicting success with reduced dosing frequency of tralokinumab in patients with moderate-to-severe atopic dermatitis.

Basic Emollients for Xerosis Cutis in Atopic Dermatitis: A Review of Clinical Studies.

Obesity is linked to disease severity in moderate to severe atopic dermatitis-Data from the prospective observational TREATgermany registry.

Basic Emollients for the Management of Xerosis Cutis: Biophysical Properties, Clinical Evidence, and Practical Considerations.

Lebrikizumab provides stable skin response with no or minimal fluctuations for up to 2 years in patients with atopic dermatitis.

Perceptions of a Group of Experts on the Integration of Artificial Intelligence in the Management of Atopic Dermatitis

Combining treat‐to‐target principles and shared decision‐making: International expert consensus‐based recommendations with a novel concept for minimal disease activity criteria in atopic dermatitis

OX40 in the Pathogenesis of Atopic Dermatitis-A New Therapeutic Target.

Efficacy and Safety of Nemolizumab in Patients With Moderate to Severe Prurigo Nodularis

Atopic dermatitis: A global health perspective.

Combining treat-to-target principles and shared decision-making: International expert consensus-based recommendations with a novel concept for minimal disease activity criteria in atopic dermatitis.

Navigating the evolving landscape of atopic dermatitis: Challenges and future opportunities: The 4th Davos declaration

A large language model artificial intelligence for patient queries in atopic dermatitis

S3 Guideline Atopic dermatitis: Part 1 ‐ General aspects, topical and non‐drug therapies, special patient groups

Patients with Moderate-to-Severe Atopic Dermatitis Maintain Stable Response with No or Minimal Fluctuations with 1 Year of Lebrikizumab Treatment

Italian S3-Guideline on the treatment of Atopic Eczema - Part 1: Systemic therapy, adapted from EuroGuiDerm by the Italian Society of Dermatology and STD (SIDEMAST), the Italian Association of Hospital Dermatologists (ADOI) and the Italian Society of Allergological and Environmental Dermatology (SIDAPA)

Skin Barrier Function Assessment: Electrical Impedance Spectroscopy Is Less Influenced by Daily Routine Activities Than Transepidermal Water Loss.

Patient-reported burden in adults with atopic dermatitis: an international qualitative study.

Treat-to-target in dermatology: A scoping review and International Eczema Council survey on the approach in atopic dermatitis.

Patients with Moderate-to-Severe Atopic Dermatitis Maintain Stable Response with No or Minimal Fluctuations with 1 Year of Lebrikizumab Treatment.

Baricitinib treatment rapidly improves the four signs of atopic dermatitis assessed by Eczema Area and Severity Index (EASI) clinical subscores.